Months after its dozen scientists began working in secret on what’s been called “the most clever CRISPR gadget” so far, the latest company hoping to deploy genome-editing to cure diseases came out of stealth mode on Monday.

Beam Therapeutics, which registered as a corporation in Massachusetts in March and has been doing experiments since last year, is debuting as CRISPR companies are popping up like dandelions, but right out of the gate Beam stands out in a crowded field. Its three founders are among the world’s leading CRISPR’ers, Editas Medicine (EDIT) has an equity stake, and in addition to the $13 million it’s raised (from Arch Venture Partners and F-Prime Capital Partners), it has commitments for another $85 million.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy